Document Detail


Should all patients with cardiovascular disease receive statin therapy?
MedLine Citation:
PMID:  11383372     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
With the strong correlation between the development of coronary heart disease and elevated levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C), therapies that significantly lower lipid levels will be widely prescribed. Within the past 15 years, major studies have shown the statins to be very effective in lowering LDL-C levels. Are the effects of statin therapy powerful enough to justify administering one of these drugs to every patient with cardiovascular disease? Among the arguments favoring its general usage are its safety record, its high rate of patient compliance (especially in comparison to alternative therapies such as diet and exercise), and its cost effectiveness. On the other hand, elevated levels of LDL-C are not the only cause of atherosclerosis, so simply lowering the LDL-C level is not the sole answer to reducing the risk of mortality and morbidity from coronary heart disease.
Authors:
R Vogel; E Schaefer
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of managed care     Volume:  7     ISSN:  1088-0224     ISO Abbreviation:  Am J Manag Care     Publication Date:  2001 May 
Date Detail:
Created Date:  2001-05-31     Completed Date:  2001-06-21     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9613960     Medline TA:  Am J Manag Care     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S117-24     Citation Subset:  H    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / adverse effects,  therapeutic use*
Cardiovascular Diseases / blood,  drug therapy*
Cost-Benefit Analysis
Drug Costs
Drug Utilization / standards
Humans
Lipoproteins, LDL / blood*,  economics
Lovastatin / adverse effects,  therapeutic use
Patient Compliance
Risk Factors
Treatment Outcome
United States
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Lipoproteins, LDL; 75330-75-5/Lovastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Supplemental fat in the diet of horses...is it advantageous?
Next Document:  Threshold level or not for low-density lipoprotein cholesterol.